Pure Global
NCT05908695

An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease

A 36-week, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of Sodium Oligomannate (GV-971) in Treatment of Mild to Moderate Alzheimer's Disease
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.·Phase 4·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Alzheimer's Disease
Drug/Device/Intervention
GV-971
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Location
Beijing,Beijing,Beijing,Xiamen,Guangzhou,Guangzhou,Nanning,Shijiazhuang,Shijiazhuang,Shijiazhuang,Tangshan,Nanyang,Zhengzhou,Chenzhou,Yueyang,Huai'an,Nanjing,Nantong,Xuzhou,Yangzhou,Jiujiang,Nanchang,, China
Timeline & enrollment
Phase
Phase 4
Start date
Jul 01, 2023
End date
Dec 01, 2029
Enrollment
1312 participants
Primary outcome

Change from baseline in the ADAS-cog/12 score,Change from baseline in ADCS-ADL23 score

Summary

The primary purpose of this study is to confirm the clinical efficacy and mechanism of action
 of GV-971, and identify incidence of known adverse reactions in long-term use and observe new
 adverse reactions, providing more guidance for clinical use.

ICD-10 classifications
Alzheimer diseaseAlzheimer disease, unspecifiedOther Alzheimer diseaseDementia in Alzheimer diseaseDementia in Alzheimer disease, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05908695
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05908695 through Pure Global AI's free database. This Phase 4 trial is sponsored by Green Valley (Shanghai) Pharmaceuticals Co., Ltd. and is currently Not yet recruiting. The study focuses on Alzheimer's Disease. Target enrollment is 1312 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.